Your browser doesn't support javascript.
loading
Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue.
Cooper, Colin S; Eeles, Rosalind; Wedge, David C; Van Loo, Peter; Gundem, Gunes; Alexandrov, Ludmil B; Kremeyer, Barbara; Butler, Adam; Lynch, Andrew G; Camacho, Niedzica; Massie, Charlie E; Kay, Jonathan; Luxton, Hayley J; Edwards, Sandra; Kote-Jarai, ZSofia; Dennis, Nening; Merson, Sue; Leongamornlert, Daniel; Zamora, Jorge; Corbishley, Cathy; Thomas, Sarah; Nik-Zainal, Serena; O'Meara, Sarah; Matthews, Lucy; Clark, Jeremy; Hurst, Rachel; Mithen, Richard; Bristow, Robert G; Boutros, Paul C; Fraser, Michael; Cooke, Susanna; Raine, Keiran; Jones, David; Menzies, Andrew; Stebbings, Lucy; Hinton, Jon; Teague, Jon; McLaren, Stuart; Mudie, Laura; Hardy, Claire; Anderson, Elizabeth; Joseph, Olivia; Goody, Victoria; Robinson, Ben; Maddison, Mark; Gamble, Stephen; Greenman, Christopher; Berney, Dan; Hazell, Steven; Livni, Naomi.
Afiliação
  • Cooper CS; Division of Genetics and Epidemiology, The Institute Of Cancer Research, London, UK.
  • Eeles R; Department of Biological Sciences University of East Anglia, Norwich, UK.
  • Wedge DC; Norwich Medical School, University of East Anglia, Norwich, UK.
  • Van Loo P; Division of Genetics and Epidemiology, The Institute Of Cancer Research, London, UK.
  • Gundem G; Royal Marsden NHS Foundation Trust, London and Sutton, UK.
  • Alexandrov LB; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK.
  • Kremeyer B; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK.
  • Butler A; Human Genome Laboratory, Department of Human Genetics, VIB and KU Leuven, Leuven, Belgium.
  • Lynch AG; Cancer Research UK London Research Institute, London, UK.
  • Camacho N; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK.
  • Massie CE; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK.
  • Kay J; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK.
  • Luxton HJ; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK.
  • Edwards S; Statistics and Computational Biology Laboratory, Cancer Research UK Cambridge Research Institute, Cambridge, UK.
  • Kote-Jarai Z; Division of Genetics and Epidemiology, The Institute Of Cancer Research, London, UK.
  • Dennis N; Urological Research Laboratory, Cancer Research UK Cambridge Research Institute, Cambridge, UK.
  • Merson S; Urological Research Laboratory, Cancer Research UK Cambridge Research Institute, Cambridge, UK.
  • Leongamornlert D; Urological Research Laboratory, Cancer Research UK Cambridge Research Institute, Cambridge, UK.
  • Zamora J; Division of Genetics and Epidemiology, The Institute Of Cancer Research, London, UK.
  • Corbishley C; Division of Genetics and Epidemiology, The Institute Of Cancer Research, London, UK.
  • Thomas S; Royal Marsden NHS Foundation Trust, London and Sutton, UK.
  • Nik-Zainal S; Division of Genetics and Epidemiology, The Institute Of Cancer Research, London, UK.
  • O'Meara S; Division of Genetics and Epidemiology, The Institute Of Cancer Research, London, UK.
  • Matthews L; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK.
  • Clark J; Department of Histopathology, St Georges Hospital, London, UK.
  • Hurst R; Royal Marsden NHS Foundation Trust, London and Sutton, UK.
  • Mithen R; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK.
  • Bristow RG; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK.
  • Boutros PC; Division of Genetics and Epidemiology, The Institute Of Cancer Research, London, UK.
  • Fraser M; Norwich Medical School, University of East Anglia, Norwich, UK.
  • Cooke S; Norwich Medical School, University of East Anglia, Norwich, UK.
  • Raine K; Institute of Food Research, Norwich Research Park, Norwich, UK.
  • Jones D; Department of Medical Biophysics, University of Toronto, Toronto, Canada.
  • Menzies A; Department of Radiation Oncology, University of Toronto, Toronto, Canada.
  • Stebbings L; Princess Margaret Cancer Centre-University Health Network, Toronto, Canada.
  • Hinton J; Department of Medical Biophysics, University of Toronto, Toronto, Canada.
  • Teague J; Informatics and Bio-Computing, Ontario Institute for Cancer Research, Toronto, Canada.
  • McLaren S; Department Pharmacology & Toxicology, University of Toronto, Toronto, Canada.
  • Mudie L; Department of Radiation Oncology, University of Toronto, Toronto, Canada.
  • Hardy C; Princess Margaret Cancer Centre-University Health Network, Toronto, Canada.
  • Anderson E; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK.
  • Joseph O; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK.
  • Goody V; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK.
  • Robinson B; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK.
  • Maddison M; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK.
  • Gamble S; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK.
  • Greenman C; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK.
  • Berney D; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK.
  • Hazell S; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK.
  • Livni N; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK.
Nat Genet ; 47(4): 367-372, 2015 Apr.
Article em En | MEDLINE | ID: mdl-25730763
Genome-wide DNA sequencing was used to decrypt the phylogeny of multiple samples from distinct areas of cancer and morphologically normal tissue taken from the prostates of three men. Mutations were present at high levels in morphologically normal tissue distant from the cancer, reflecting clonal expansions, and the underlying mutational processes at work in morphologically normal tissue were also at work in cancer. Our observations demonstrate the existence of ongoing abnormal mutational processes, consistent with field effects, underlying carcinogenesis. This mechanism gives rise to extensive branching evolution and cancer clone mixing, as exemplified by the coexistence of multiple cancer lineages harboring distinct ERG fusions within a single cancer nodule. Subsets of mutations were shared either by morphologically normal and malignant tissues or between different ERG lineages, indicating earlier or separate clonal cell expansions. Our observations inform on the origin of multifocal disease and have implications for prostate cancer therapy in individual cases.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Próstata / Neoplasias da Próstata / Análise Mutacional de DNA / Evolução Clonal / Neoplasias Primárias Múltiplas Tipo de estudo: Observational_studies Limite: Humans / Male Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Próstata / Neoplasias da Próstata / Análise Mutacional de DNA / Evolução Clonal / Neoplasias Primárias Múltiplas Tipo de estudo: Observational_studies Limite: Humans / Male Idioma: En Ano de publicação: 2015 Tipo de documento: Article